Details of the Drug

General Information of Drug (ID: DMG2SKR)

Drug Name

Tedizolid

Synonyms

Tedizolid; Torezolid; 856866-72-3; TR-700; Da 7157; UNII-97HLQ82NGL; DA-7157; TR 700; 97HLQ82NGL; CHEBI:82717; (5R)-3-[3-fluoro-4-[6-(2-methyltetrazol-5-yl)-3-pyridyl]phenyl]-5-(hydroxymethyl)oxazolidin-2-one; Tedizolid [USAN:INN]; Tedizolid (USAN/INN); SCHEMBL440398; CHEMBL1257051; DTXSID10234975; XFALPSLJIHVRKE-GFCCVEGCSA-N; MolPort-042-624-220; AI025; BCP02830; ZINC43100956; AKOS025401974; CS-0687; NCGC00379072-02; AN-27109; AK322133; AC-27738; BC600578; HY-14855

Indication

Disease Entry	ICD 11	Status	REF
Skin infection	1F28-1G0Z	Approved	[1]
------------------------------------------------------------------------------------

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

370.3

Logarithm of the Partition Coefficient (xlogp)

1.4

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

Absorption AUC: The area under the plot of plasma concentration (AUC) of drug is 23.8-25.6 mgh/L [2]
Absorption Cmax: The maximum plasma concentration (Cmax) of drug is 2.0-2.2 mg/L [2]
Absorption Tmax: The time to maximum plasma concentration (Tmax) is 2.5-3.5 h [2]
BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [3]
Bioavailability: The bioavailability of drug is 91% [2]
Clearance: The apparent oral clearance of drug is 6.9 +/- 1.7 L/h [2]
Elimination: When given as a single oral dose, approximately 82% of tedizolid is excreted via the feces and 18% in urine [2]
Half-life: The concentration or amount of drug in body reduced by one-half in 12 hours [2]
Metabolism: The drug is metabolized via the liver [2]
Vd: The volume of distribution (Vd) of drug is 67-80 L [2]

Chemical Identifiers

Formula: C17H15FN6O3
IUPAC Name: (5R)-3-[3-fluoro-4-[6-(2-methyltetrazol-5-yl)pyridin-3-yl]phenyl]-5-(hydroxymethyl)-1,3-oxazolidin-2-one
Canonical SMILES: CN1N=C(N=N1)C2=NC=C(C=C2)C3=C(C=C(C=C3)N4C[C@@H](OC4=O)CO)F
InChI: InChI=1S/C17H15FN6O3/c1-23-21-16(20-22-23)15-5-2-10(7-19-15)13-4-3-11(6-14(13)18)24-8-12(9-25)27-17(24)26/h2-7,12,25H,8-9H2,1H3/t12-/m1/s1
InChIKey: XFALPSLJIHVRKE-GFCCVEGCSA-N

Cross-matching ID

PubChem CID: 11234049
ChEBI ID: CHEBI:82717
CAS Number: 856866-72-3
DrugBank ID: DB14569
TTD ID: D08KBK

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Bacterial 50S ribosomal RNA (Bact 50S rRNA)	TTUWYEA	NOUNIPROTAC	Modulator	[4]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Tedizolid (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Berotralstat	DMWA2DZ	Major	Decreased clearance of Tedizolid due to the transporter inhibition by Berotralstat.	Innate/adaptive immunodeficiency [4A00]	[5]
Ubrogepant	DM749I3	Moderate	Decreased clearance of Tedizolid due to the transporter inhibition by Ubrogepant.	Migraine [8A80]	[6]
-----------

References

1	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
2	FDA Approved Products: Sivextro (tedizolid phosphate) tablet and injection
3	BDDCS predictions, self-correcting aspects of BDDCS assignments, BDDCS assignment corrections, and classification for more than 175 additional drugs
4	2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
5	Product Information. Orladeyo (berotralstat). BioCryst Pharmaceuticals Inc, Durham, NC.
6	Product Information. Ubrelvy (ubrogepant). Allergan Inc, Irvine, CA.